These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
343 related articles for article (PubMed ID: 10682229)
1. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group. Clin Neuropharmacol; 2000; 23(1):34-44. PubMed ID: 10682229 [TBL] [Abstract][Full Text] [Related]
2. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. Parkinson Study Group JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889 [TBL] [Abstract][Full Text] [Related]
3. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. Parkinson Study Group JAMA; 2002 Apr; 287(13):1653-61. PubMed ID: 11926889 [TBL] [Abstract][Full Text] [Related]
4. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A; Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734 [TBL] [Abstract][Full Text] [Related]
6. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Parkinson Study Group CALM Cohort Investigators Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group. JAMA; 1997 Jul; 278(2):125-30. PubMed ID: 9214527 [TBL] [Abstract][Full Text] [Related]
9. Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease. Clarke C E; Speller J M; Clarke J A Cochrane Database Syst Rev; 2000; 2000(3):CD002259. PubMed ID: 10908539 [TBL] [Abstract][Full Text] [Related]
10. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease. Dooley M; Markham A Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397 [TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease. Wong KS; Lu CS; Shan DE; Yang CC; Tsoi TH; Mok V J Neurol Sci; 2003 Dec; 216(1):81-7. PubMed ID: 14607306 [TBL] [Abstract][Full Text] [Related]
12. Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life. Noyes K; Dick AW; Holloway RG; Value Health; 2006; 9(1):28-38. PubMed ID: 16441522 [TBL] [Abstract][Full Text] [Related]
13. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness. Noyes K; Dick AW; Holloway RG; Pharmacoeconomics; 2005; 23(12):1257-70. PubMed ID: 16336019 [TBL] [Abstract][Full Text] [Related]
14. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. Molho ES; Factor SA; Weiner WJ; Sanchez-Ramos JR; Singer C; Shulman L; Brown D; Sheldon C J Neural Transm Suppl; 1995; 45():225-30. PubMed ID: 8748629 [TBL] [Abstract][Full Text] [Related]
15. Does levodopa slow or hasten the rate of progression of Parkinson's disease? Fahn S; J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436 [TBL] [Abstract][Full Text] [Related]
16. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. Inzelberg R; Schechtman E; Nisipeanu P Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891 [TBL] [Abstract][Full Text] [Related]
17. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial. Noyes K; Dick AW; Holloway RG; Med Decis Making; 2004; 24(5):472-85. PubMed ID: 15358996 [TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation. Haycox A; Armand C; Murteira S; Cochran J; François C Drugs Aging; 2009; 26(9):791-801. PubMed ID: 19728752 [TBL] [Abstract][Full Text] [Related]
19. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test. Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263 [TBL] [Abstract][Full Text] [Related]
20. Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease. Bennett JP; Piercey MF J Neurol Sci; 1999 Feb; 163(1):25-31. PubMed ID: 10223406 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]